

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.


Authorization for this examiner's amendment was given in a telephone interview with Thomas Weber on 5/20/09.

The application has been amended as follows:

IN THE CLAIMS

Please replace the current claim set with the following:


1. (Currently Amended) ~~A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury composition,~~ which comprises as an active ingredient a substance selected from a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, and a solvate thereof.~~



wherein one of R¹ and R² represents hydrogen atom and the other represents the formula

- X - A wherein A represents a hydrogen atom, a hydrocarbon-carbonyl group, or a hydrocarbon-sulfonyl group, X represents an oxygen atom or NH; one of R³ and R⁴ represents hydrogen atom and the other represents the following formula:

Art Unit: 1621



wherein

Y represents a sulfonyl group or a carbonyl group,

R⁵ represents

a phenyl group which may be substituted with one or more substituents selected from


a halogen atom,
 a nitro group,
 an alkyl group,
 a halogenated alkyl group,
 a hydroxyl group,
 an alkoxy group,
 an alkylendioxy group,
 an amino group,
 an N,N-di(alkyl)-amino group, and
 an alkyl-sulfonyl group,

a naphthyl group which may be substituted,
 a furyl group which may be substituted,
 a pyridyl group which may be substituted,
 a benzimidazolyl group which may be substituted, or
 a cycloalkyl group,

Z represents a single bond or a C₁ to C₄ alkylene group,R⁶ represents hydrogen atom or a C₁ to C₆ alkyl group,

with the following provisos:

a compound represented by the following formula:



Art Unit: 1621

wherein each of A, Z, R⁵ and R⁶ has the same meaning as that defined above is excluded;
when one of R¹ and R² is the formula - O - A, A is a hydrogen atom, Y is a carbonyl group, Z is a single bond, and R⁶ is hydrogen atom, then R⁵ is

a phenyl group which may be substituted with one or more substituents selected from

- a halogen atom,
- a nitro group,
- an alkyl group,
- a halogenated alkyl group,
- an alkoxy group,
- an alkylenedioxy group,
- an amino group,
- an N,N-di(alkyl)-amino group, and
- an alkyl-sulfonyl group,

- a naphthyl group which may be substituted,
- a furyl group which may be substituted,
- a pyridyl group which may be substituted,
- a benzimidazolyl group which may be substituted, or
- a cycloalkyl group;

when R² is the formula - NH - A, A is a hydrogen atom, ~~R⁴ is a hydrogen atom,~~ Y is a sulfonyl group, Z is a C₁ alkylene group, and R⁶ is hydrogen atom, then R⁵ is

a phenyl group which is substituted with one or more substituents selected from

- a halogen atom,
- a nitro group,
- an alkyl group,
- a halogenated alkyl group,
- a hydroxyl group,
- an alkoxy group,
- an alkylenedioxy group,
- an amino group,
- an N,N-di(alkyl)-amino group, and
- an alkyl-sulfonyl group,

- a naphthyl group which may be substituted,
- a furyl group which may be substituted,
- a pyridyl group which may be substituted,
- a benzimidazolyl group which may be substituted, or
- a cycloalkyl group;

Art Unit: 1621

when R^1 is the formula $-NH-A$, A is a hydrogen atom, R^3 is a hydrogen atom, Y is a sulfonyl group, Z is a C_1 alkylene group, and R^6 is hydrogen atom, then R^5 is

a phenyl group which is substituted with one or more substituents selected from

- a halogen atom,
- a nitro group,
- an alkyl group,
- a halogenated alkyl group,
- a hydroxyl group,
- an alkoxy group,
- an alkylenedioxy group,
- an amino group,
- an N,N-di(alkyl)-amino group, and
- an alkyl-sulfonyl group,

- a naphthyl group which may be substituted,
- a furyl group which may be substituted,
- a pyridyl group which may be substituted,
- a benzimidazolyl group which may be substituted, or
- a cycloalkyl group; and

when one of R^1 and R^2 is the formula $-NH-A$, A is a hydrogen atom, Y is a sulfonyl group, Z is a single bond, and R^6 is hydrogen atom, then R^5 is

a phenyl group which may be substituted with one or more substituents selected from

- a halogen atom,
- a nitro group,
- an alkyl group,
- a halogenated alkyl group,
- a hydroxyl group,
- an alkoxy group,
- an alkylenedioxy group,
- an amino group,
- an N,N-di(alkyl)-amino group, and
- an alkyl-sulfonyl group,

- a naphthyl group which may be substituted,
- a furyl group which may be substituted,
- a pyridyl group which may be substituted, or
- a benzimidazolyl group which may be substituted.

2. (Canceled)

Art Unit: 1621

3. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein Z is a methylene group, an ethylene group, an ethane-1,1-diyl group, a propane-1,3-diyl group, a propane-1,2-diyl group, a propane-2,2-diyl group, or a butane-1,4-diyl group.

4. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein Y is a sulfonyl group.

5. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein R¹ is a group represented by the formula - X - A wherein A represents a hydrogen atom, a hydrocarbon-carbonyl group, or a hydrocarbon-sulfonyl group, X represents an oxygen atom or NH, and R² is a hydrogen atom.


6. (Canceled)

7. (Currently Amended) The ~~medicament~~ composition according to ~~claim 6, wherein the claim 1, further comprising an~~ anticancer agent is selected from bleomycin, adriamycin, cisplatin, cyclophosphamide, mitomycin C, and derivatives thereof.

8. (Currently Amended) The ~~medicament~~ composition according to claim 1, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

9. (Canceled)

10. (Currently Amended) A compound represented by the general formula (I)[[,]] or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, or a solvate thereof~~ according to claim 1, provided that the following compound is excluded:



11. (Currently Amended) A compound selected from the following compounds or a pharmacologically acceptable salt thereof, ~~or a hydrate thereof or a solvate thereof~~:

Art Unit: 1621

N-Benzyl-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2,6-Difluorobenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2,4-Dichlorobenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3-Nitrobenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(4-Nitrobenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2-Methylbenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[2-(Trifluoromethyl)benzyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3,4-Dihydroxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2-Methoxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3-Methoxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2,3-Dimethoxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3,5-Dimethoxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3,4-Methylenedioxybenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(3-Aminobenzyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[4-(Dimethylamino)benzyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[4-(Methanesulfonyl)benzyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(1-Naphthylmethyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[(Pyridin-2-yl)methyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-[(Benzimidazol-2-yl)methyl]-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-Cyclohexylmethyl-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-Phenyl-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(2-Phenethyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-(1-Phenethyl)-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-Benzyl-N-methyl-5-{{[(4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;
N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;
N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

Art Unit: 1621

N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-(3,4-Dihydroxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3,5-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;
N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;
5-Acetyloxy-N-benzyl-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2,4-dichlorobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(3-nitrobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[4-(tert-butyl)benzyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2,3-dimethoxybenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(3-aminobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(1-naphthylmethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[(pyridin-2-yl)methyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(cyclohexylmethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-phenyl-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2-phenethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(1-phenethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-benzyl-N-methyl-naphthalene-2-sulfonamide;
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

Art Unit: 1621

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;
N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;
N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;
6-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Amino-N-benzyl-naphthalene-1-carboxamide;
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

12. (Currently Amended) A ~~medicament~~ composition which comprises as an active ingredient a substance selected from a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, and a solvate thereof~~ according to claim 10.

13. (Canceled)

14.-16. (Canceled)

17. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein R⁵ is a substituted phenyl group.

18. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein the compound is selected from the following compounds:

N-Benzyl-5- {[(4-methylphenyl)sulfonyl]oxy } naphthalene-1-sulfonamide;
N-(2,6-Difluorobenzyl)-5- {[(4-methylphenyl)sulfonyl]oxy } naphthalene-1-sulfonamide;
N-(2,4-Dichlorobenzyl)-5- {[(4-methylphenyl)sulfonyl]oxy } naphthalene-1-sulfonamide;
N-(3-Nitrobenzyl)-5- {[(4-methylphenyl)sulfonyl]oxy } naphthalene-1-sulfonamide;
N-(4-Nitrobenzyl)-5- {[(4-methylphenyl)sulfonyl]oxy } naphthalene-1-sulfonamide;

Art Unit: 1621

N-(2-Methylbenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[2-(Trifluoromethyl)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(3,4-Dihydroxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(2-Methoxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(3-Methoxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(2,3-Dimethoxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(3,5-Dimethoxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(3,4-Methylenedioxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(3-Aminobenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[4-(Dimethylamino)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[4-(Methanesulfonyl)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(1-Naphthylmethyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[(Pyridin-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-[(Benzimidazol-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-Cyclohexylmethyl-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-Phenyl-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(2-Phenethyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-(1-Phenethyl)-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-Benzyl-N-methyl-5-{{(4-methylphenyl)sulfonyl}oxy} naphthalene-1-sulfonamide;
N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;
N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-(3,4-Dihydroxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;

Art Unit: 1621

N-(2,3-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3,5-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;
N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;
N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;
N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;
5-Acetyloxy-N-benzyl-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2,4-dichlorobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(3-nitrobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[4-(tert-butyl)benzyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2,3-dimethoxybenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(3-aminobenzyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(1-naphthylmethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-[(pyridin-2-yl)methyl]-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(cyclohexylmethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-phenyl-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(2-phenethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-(1-phenethyl)-naphthalene-2-sulfonamide;
5-Acetyloxy-N-benzyl-N-methyl-naphthalene-2-sulfonamide;
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;
N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;
N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

Art Unit: 1621

N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;
6-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
~~6-Amino-N-benzyl-naphthalene-2-sulfonamide;~~
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;
5-Amino-N-benzyl-naphthalene-1-carboxamide;
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

19. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein the compound is N-[4-(tert-butyl)benzyl]-5-[[4-(methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide.

20.-24. (Canceled)

25. (Currently Amended) The compound according to claim 10[[,]] or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, or a solvate thereof~~, wherein A is a hydrogen atom, an acetyl group, or a para-toluenesulfonyl group.

26. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein A is a hydrogen atom, an alkyl-carbonyl group, or an aryl-sulfonyl group which may be substituted with one or more alkyl groups.

27. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein A is a hydrogen atom, an acetyl group, or a para-toluenesulfonyl group.

28. (Currently Amended) The ~~medicament~~ composition according to claim 1, wherein R⁵ is a phenyl group, 2,6-difluorophenyl group, 2,4-dichlorophenyl group, 3-nitrophenyl group, 4-nitrophenyl group, 2-methylphenyl group, 4-(tert-butyl)phenyl group, 2-(trifluoromethyl)phenyl group, 4-(trifluoromethyl)phenyl group, 3,4-dihydroxyphenyl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 2,3-dimethoxyphenyl group, 3,5-dimethoxyphenyl group, 3,4-methylenedioxyphenyl group, 3-aminophenyl group, 4-(dimethylamino)phenyl group, 4-

Art Unit: 1621

methanesulfonylphenyl group, 1-naphthyl group, 5-methylfuran-2-yl group, pyridin-2-yl group, benzimidazol-2-yl group, or cyclohexyl group.

29. (Currently Amended) The compound according to claim 10[[,]] or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, or a solvate thereof~~, wherein Z is a methylene group, an ethylene group, an ethane-1,1-diyl group, a propane-1,3-diyl group, a propane-1,2-diyl group, a propane-2,2-diyl group, or a butane-1,4-diyl group.

30. (Currently Amended) The compound according to claim 10[[,]] or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, or a solvate thereof~~, wherein A is a hydrogen atom, an alkyl-carbonyl group, or an aryl-sulfonyl group which may be substituted with one or more alkyl groups.

31. (Currently Amended) The compound according to claim 10[[,]] or a pharmacologically acceptable salt thereof, ~~a hydrate thereof, or a solvate thereof~~, wherein R⁵ is a phenyl group, 2,6-difluorophenyl group, 2,4-dichlorophenyl group, 3-nitrophenyl group, 4-nitrophenyl group, 2-methylphenyl group, 4-(tert-butyl)phenyl group, 2-(trifluoromethyl)phenyl group, 4-(trifluoromethyl)phenyl group, 3,4-dihydroxyphenyl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 2,3-dimethoxyphenyl group, 3,5-dimethoxyphenyl group, 3,4-methylenedioxyphenyl group, 3-aminophenyl group, 4-(dimethylamino)phenyl group, 4-methanesulfonylphenyl group, 1-naphthyl group, 5-methylfuran-2-yl group, pyridin-2-yl group, benzimidazol-2-yl group, or cyclohexyl group.

32. (Currently Amended) The ~~medicament composition~~ according to claim 12, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

33. (Currently Amended) The ~~medicament composition~~ according to claim 12, which is used for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yevgeny Valenrod whose telephone number is 571-272-9049. The examiner can normally be reached on 8:30am-5:00pm M-F.

Art Unit: 1621

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel Sullivan can be reached on 571-272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Yevgeny Valenrod/

Yevgeny Valenrod
Patent Examiner
Technology Center 1600

/Paul A. Zucker/
Primary Examiner, Art Unit 1621